User talk:Z3332250: Difference between revisions

From Embryology
No edit summary
No edit summary
Line 1: Line 1:
=Articles to read:=
=Articles to read:=


=="""Carido"""==
*http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1728941/?tool=pmcentrez
*http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1728941/?tool=pmcentrez
*http://www.ncbi.nlm.nih.gov/pubmed/2940284
*http://www.ncbi.nlm.nih.gov/pubmed/2940284
Line 6: Line 7:
*http://www.ncbi.nlm.nih.gov/pubmed/2944367
*http://www.ncbi.nlm.nih.gov/pubmed/2944367
*http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1894724/?tool=pmcentrez
*http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1894724/?tool=pmcentrez
----
<ref name="PMID19283344"><pubmed>19283344</pubmed></ref>
=Treatment=
friedreich Ataxia (FA) a progressive neurological congenital disorder<ref name="PMID19283349"><pubmed>19283349</pubmed></ref>, wtih no treatment identified only possible pharmaceutics which can reduce the progression of FA however not significantly. Whereas significant treatment poties  of FA or reduction in progression are the following:
*Iron-chelation
**deferoxamine
*Antioxidants:
**Idebenone
**Coenzyme Q10

Revision as of 23:25, 6 September 2011

Articles to read:

"""Carido"""


[1]

Treatment

friedreich Ataxia (FA) a progressive neurological congenital disorder[2], wtih no treatment identified only possible pharmaceutics which can reduce the progression of FA however not significantly. Whereas significant treatment poties of FA or reduction in progression are the following:

  • Iron-chelation
    • deferoxamine
  • Antioxidants:
    • Idebenone
    • Coenzyme Q10
  1. <pubmed>19283344</pubmed>
  2. <pubmed>19283349</pubmed>